{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T12:26:04Z","timestamp":1771071964576,"version":"3.50.1"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The\n            <jats:italic>in vitro<\/jats:italic>\n            antibacterial activity of solithromycin (CEM-101) against macrolide-resistant isolates (\n            <jats:italic>n<\/jats:italic>\n            = 62) of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Streptococcus agalactiae<\/jats:named-content>\n            (group B streptococcus [GBS]) was determined. Phenotypic characterization of macrolide-resistant strains was performed by double-disc diffusion testing. A multiplex PCR was used to identify the\n            <jats:italic>erm<\/jats:italic>\n            (B),\n            <jats:italic>erm<\/jats:italic>\n            (TR), and\n            <jats:italic>mef<\/jats:italic>\n            (A\/E) genes, capsular genotypes, and alpha-like (Alp) protein genes from the GBS strains. Determination of MIC was carried out using the microdilution broth method. The Etest method was used for penicillin, azithromycin, clarithromycin, and erythromycin. Solithromycin had a MIC\n            <jats:sub>50<\/jats:sub>\n            of \u22640.008 \u03bcg\/ml and a MIC\n            <jats:sub>90<\/jats:sub>\n            of 0.015 \u03bcg\/ml against macrolide-susceptible\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. agalactiae<\/jats:named-content>\n            . These MICs were lower than those displayed by penicillin (MIC\n            <jats:sub>50<\/jats:sub>\n            of 0.032 \u03bcg\/ml and MIC\n            <jats:sub>90<\/jats:sub>\n            of 0.047 \u03bcg\/ml), the antibiotic agent of choice for prophylaxis and treatment of GBS infections. Against macrolide-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. agalactiae<\/jats:named-content>\n            , solithromycin had a MIC\n            <jats:sub>50<\/jats:sub>\n            of 0.03 \u03bcg\/ml and a MIC\n            <jats:sub>90<\/jats:sub>\n            of 0.125 \u03bcg\/ml. Against\n            <jats:italic>erm<\/jats:italic>\n            (B) strains, solithromycin had a MIC\n            <jats:sub>50<\/jats:sub>\n            of 0.03 \u03bcg\/ml and a MIC\n            <jats:sub>90<\/jats:sub>\n            of 0.06 \u03bcg\/ml, while against\n            <jats:italic>mef<\/jats:italic>\n            (A) strains, it had a MIC\n            <jats:sub>50<\/jats:sub>\n            of 0.03 \u03bcg\/ml and a MIC\n            <jats:sub>90<\/jats:sub>\n            of 0.125 \u03bcg\/ml. Most erythromycin-resistant GBS strains were of serotype V (64.5%) and associated significantly with\n            <jats:italic>alp2-3<\/jats:italic>\n            . Moreover, a statistically significant association was observed between the constitutive macrolide-lincosamide-streptogramin B resistance (cMLS\n            <jats:sub>B<\/jats:sub>\n            ) phenotype and the\n            <jats:italic>erm<\/jats:italic>\n            (B) gene-carrying strains, the\n            <jats:italic>alp2-3<\/jats:italic>\n            gene and the M phenotype, and the\n            <jats:italic>mef<\/jats:italic>\n            (A\/E) gene and\n            <jats:italic>epsilon<\/jats:italic>\n            . Overall, our results show that solithromycin had lower or similar MICs than penicillin and potent activity against macrolide-resistant strains independent of their genotype or phenotype, representing a valid therapeutic alternative where \u03b2-lactams cannot be used.\n          <\/jats:p>","DOI":"10.1128\/aac.02210-13","type":"journal-article","created":{"date-parts":[[2013,12,31]],"date-time":"2013-12-31T02:28:14Z","timestamp":1388456894000},"page":"1693-1698","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":12,"title":["<i>In Vitro<\/i>\n            Activity of Solithromycin against Erythromycin-Resistant Streptococcus agalactiae"],"prefix":"10.1128","volume":"58","author":[{"given":"Giorgio","family":"Piccinelli","sequence":"first","affiliation":[{"name":"Institute of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhavathi","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Cempra, Inc., Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Bonfanti","sequence":"additional","affiliation":[{"name":"Institute of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Caccuri","sequence":"additional","affiliation":[{"name":"Institute of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaldo","family":"Caruso","sequence":"additional","affiliation":[{"name":"Institute of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Antonia","family":"De Francesco","sequence":"additional","affiliation":[{"name":"Institute of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"222","volume-title":"Streptococcal infections: clinical aspects, microbiology, and molecular pathogenesis","author":"Baker CJ","year":"2000","unstructured":"BakerCJ. 2000. Group B streptococcal infections, p 222\u2013237. In StevensDLKaplanEL (ed), Streptococcal infections: clinical aspects, microbiology, and molecular pathogenesis. Oxford University Press, New York, NY."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-6-199509150-00003"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15389-5"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012657"},{"key":"e_1_3_2_6_2","first-page":"35155","article-title":"Establishing a list of qualifying pathogens under the Food And Drug Administration Safety and Innovation Act. Proposed rule","volume":"78","author":"Federal Register","year":"2013","unstructured":"Federal Register. 2013. Establishing a list of qualifying pathogens under the Food And Drug Administration Safety and Innovation Act. Proposed rule. Fed. Regist. 78:35155\u201335173.","journal-title":"Fed. Regist."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00185-08"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00596-08"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-6-57"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2009.0895"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22620"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.08.004"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01123-09"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01662-09"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2009.10.013"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mimet.2009.11.010"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.3.1326-1329.2004"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.5.1875-1877.2006"},{"key":"e_1_3_2_19_2","volume-title":"M100-S20","author":"Clinical and Laboratory Standards Institute","year":"2010","unstructured":"Clinical and Laboratory Standards Institute. 2010. Performance standard for antimicrobial susceptibility testing, M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.11.2562"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.9.2144"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.12.5620-5623.2004"},{"key":"e_1_3_2_23_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, M7-A9","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, M7-A9. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_24_2","unstructured":"EUCAST. 2012. Breakpoint tables for interpretation of MICs and zone diameters version 2.0. European Committee on Antimicrobial Susceptibility Testing. 2012. http:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00461-08"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03106.x"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1495-4"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4444-4446.2004"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2525-2527.2005"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3504-3508.2001"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1889-1891.2001"},{"key":"e_1_3_2_32_2","first-page":"84","article-title":"Vaginal and rectal carriage of Streptococcus agalactiae in the Czech Republic: incidence, serotypes distribution and susceptibility to antibiotics","volume":"119","author":"Motlov\u00e1 J","year":"2004","unstructured":"Motlov\u00e1JStrakovaLUrbaskovaPSakPSeverT. 2004. Vaginal and rectal carriage of Streptococcus agalactiae in the Czech Republic: incidence, serotypes distribution and susceptibility to antibiotics. Indian J. Med. Res. 119:84\u201387.","journal-title":"Indian J. Med. Res."},{"key":"e_1_3_2_33_2","volume-title":"Binding and action of CEM-101, a new macrolide\/ketolide in development for treating infections with macrolide-resistant and macrolide-susceptible bacteria, abstr","author":"Llano-Soleto B","year":"2008","unstructured":"Llano-SoletoBKlepackiDMankinbAS. 2008. Binding and action of CEM-101, a new macrolide\/ketolide in development for treating infections with macrolide-resistant and macrolide-susceptible bacteria, abstr. F-3983. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother., 25 to 28 October 2008, Washington, DC."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1453-1457.2000"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn432"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.1.102-127.2005"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.33.10.2576-2581.1995"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00999-07"}],"updated-by":[{"DOI":"10.1128\/aac.02015-18","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:00:00Z","timestamp":1540339200000}}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02210-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02210-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:36:55Z","timestamp":1645483015000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02210-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1128\/AAC.02210-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.02210-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"2013-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-12-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-02-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}